Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics

CHRS POWR Grades

• Growth is the dimension where CHRS ranks best; there it ranks ahead of 83.8% of US stocks.
• The strongest trend for CHRS is in Growth, which has been heading up over the past 177 days.
• CHRS's current lowest rank is in the Stability metric (where it is better than 0.72% of US stocks).

CHRS Stock Summary

• The capital turnover (annual revenue relative to shareholder's equity) for CHRS is -1.58 -- better than merely 4.81% of US stocks.
• CHRS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 4.25% of US stocks.
• COHERUS BIOSCIENCES INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -45.41%, greater than the shareholder yield of merely 11.05% of stocks in our set.
• Stocks that are quantitatively similar to CHRS, based on their financial statements, market capitalization, and price volatility, are NSPR, TARS, SERA, VLCN, and CLPT.
• Visit CHRS's SEC page to see the company's official filings. To visit the company's web site, go to www.coherus.com.

CHRS Valuation Summary

• In comparison to the median Healthcare stock, CHRS's price/sales ratio is 47.22% lower, now standing at 1.9.
• CHRS's EV/EBIT ratio has moved up 1.2 over the prior 109 months.

Below are key valuation metrics over time for CHRS.

CHRS Growth Metrics

The year over year revenue growth rate now stands at -31.41%.
• Its year over year net income to common stockholders growth rate is now at -175.63%.
• The 2 year cash and equivalents growth rate now stands at 68.53%.

Over the past 67 months, CHRS's revenue has gone up $61,153,000.

The table below shows CHRS's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	239.061	-193.493	-278.609
2022-06-30	276.14	-142.693	-230.487
2022-03-31	303.632	-92.844	-210.237
2021-12-31	326.551	-37.432	-287.1
2021-09-30	363.599	48.014	-231.667
2021-06-30	394.647	81.656	-165.206

CHRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CHRS has a Quality Grade of B, ranking ahead of 82.07% of graded US stocks.
• CHRS's asset turnover comes in at 0.513 -- ranking 78th of 682 Pharmaceutical Products stocks.
• CPRX, XTNT, and VIVO are the stocks whose asset turnover ratios are most correlated with CHRS.

The table below shows CHRS's key quality metrics over time.